

GULF MEDICAL PROJECTS COMPANY
PUBLIC SHAREHOLDING COMPANY

**REVIEW REPORT AND CONDENSED CONSOLIDATED
INTERIM FINANCIAL STATEMENTS FOR THE
SIX MONTHS PERIOD ENDED
30 JUNE 2026**

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim financial statements

For the Six months period ended 30 June 2026

INDEX	<u>Page</u>	<u>Exhibit</u>
Review Report on Condensed Consolidated Interim Financial Statements	1	--
Condensed Consolidated Interim Statement of Financial Position	2	A
Condensed Consolidated Interim Statement of Income	3	B
Condensed Consolidated Interim Statement of Comprehensive Income	4	B (Continued)
Condensed Consolidated Interim Statement of Changes in Equity	5	C
Condensed Consolidated Interim Statement of Cash Flows	6	D
Notes to the Condensed Consolidated Interim Financial Statements	7 – 22	--

101380404

**Review Report on Condensed Consolidated Interim
Financial Statements to the Board of Directors of
Gulf Medical Projects Company
Public Shareholding Company**

Introduction

We have reviewed the accompanying condensed consolidated interim financial statements of **Gulf Medical Projects Company (PJSC)** (the “Company”) and **Its Subsidiary** (together referred to as the “Group”) which comprise the condensed consolidated interim statement of financial position as at 30 June 2026 and the condensed consolidated interim statement of income, comprehensive income, changes in equity and cash flows for the six-months period then ended, and other explanatory notes. Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with International Accounting Standard 34 “Interim Financial Reporting”. Our responsibility is to express a conclusion on this condensed consolidated interim financial statements based on our review.


Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements as at 30 June 2026 is not prepared, in all material respects, in accordance with IAS 34, ‘Interim Financial Reporting’.

TALAL ABU-GHAZALEH & CO. INTERNATIONAL



Zaid Ali Musleh
Licensed Auditor No. 1130

Sharjah, 13 August 2026

الاتحاد الدولي للمحاسبين (نيويورك)



MEMBER OF THE

FORUM OF FIRMS

عضو منتدى الشركات الكبرى في

Al Majaz 3, Al Ghanem Business Center

Office No. 301, 302

Tel.: +971 6 537 8800

Fax: +971 6 537 8811

P.O.Box: 952 Sharjah, United Arab Emirates



tagi.com

tagco.sharjah@tagi.com

منطقة المجاز ٣، مركز الغانم للأعمال

مكتب رقم ٣٠١، ٣٠٢

هاتف: +٩٧١ ٦ ٥٣٧ ٨٨٠٠

فاكس: +٩٧١ ٦ ٥٣٧ ٨٨١١

ص.ب: ٩٥٢ الشارقة، الإمارات العربية المتحدة

GULF MEDICAL PROJECTS COMPANY (PJSC)
Condensed consolidated interim statement of financial position
As at 30 June 2026


Exhibit A

	Note	30 June 2026 (Unaudited) AED '000'	31 December 2025 (Audited) AED '000'
ASSETS			
Non-Current Assets			
Property and equipment	4	692,836	695,085
Intangible assets	5	8,174	2,500
Right-of-use assets	6	5,462	6,729
Investment properties	7	106,295	106,295
Investments at fair value through other comprehensive income (FVTOCI)	8	289,795	305,649
Total Non-Current Assets		1,102,562	1,116,258
Current Assets			
Inventories	9	34,164	27,027
Due from a related party	10	1,269	1,646
Investments at fair value through profit or loss (FVTPL)	8	62,897	60,661
Accounts receivable and others	11	140,503	118,460
Cash and bank balances	12	137,960	223,421
Total Current Assets		376,793	431,215
TOTAL ASSETS		1,479,355	1,547,473
Equity and Liabilities			
Equity			
Share capital	13	698,916	698,916
Reserves		317,074	317,074
Cumulative change in fair value of investments measured at fair value through other comprehensive income		48,353	73,252
Retained earnings		59,504	131,583
Net equity attributable to equity holders of the parent company		1,123,847	1,220,825
Non-controlling interest	14	130,423	117,692
Total Equity - Exhibit C		1,254,270	1,338,517
Non-Current Liabilities			
Employees' end of service benefits	15	33,371	31,481
Lease liabilities	16	2,337	3,100
Deferred tax liabilities	22	3,567	3,282
Total Non-Current Liabilities		39,275	37,863
Current Liabilities			
Accounts payable and others	17	169,757	158,890
Lease liabilities	16	2,728	3,168
Income tax provision	22	13,325	9,035
Total Current Liabilities		185,810	171,093
TOTAL EQUITY AND LIABILITIES		1,479,355	1,547,473

**THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

To the best of our knowledge, the financial information included in these condensed consolidated interim financial statements fairly presents in all material respects the financial condition, result of operation and cash flows of the Group as of, and for, the period presented therein.

These condensed consolidated interim financial statements were approved for issue by the Board of Directors on 13 August 2026 and signed on their behalf by :


Sheikh Dr. Faisal Bin Khalid Khalid Al Qasimi
(Chairman)

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim statement of income

For the six months period ended 30 June 2026 (Unaudited)

EXHIBIT B

	<u>Note</u>	<u>Six months period ended</u>		<u>Three months period ended</u>	
		<u>30 June 2026</u>	<u>30 June 2025</u>	<u>30 June 2026</u>	<u>30 June 2025</u>
		<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>
Revenues	19	405,239	365,419	210,850	185,366
Cost of revenues	20	(302,648)	(269,020)	(157,262)	(137,073)
Gross profit		102,591	96,399	53,588	48,293
Fair value gain/(loss) of investments at FVTPL					
Other income		2,236	6,743	(1,120)	3,205
General and administrative expenses	21	34,677	37,298	24,689	25,559
Finance cost on lease liabilities		(66,413)	(65,841)	(33,094)	(33,950)
		(48)	(74)	(23)	(36)
Profit for the period before tax – Exhibit D		73,043	74,525	44,040	43,071
Current income tax expenses	22	(4,290)	(4,234)	(2,258)	(1,995)
Deferred tax	22	(285)	(607)	7	(289)
Profit for the period		68,468	69,684	41,789	40,787
Attributable To :					
Equity holders of the parent company		55,737	57,454	34,881	34,982
Non-controlling interest		12,731	12,230	6,908	5,805
Total		68,468	69,684	41,789	40,787
Basic earnings per share (AED)	23	0.080	0.082	0.050	0.050

THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim statement of comprehensive income
For the six months period ended 30 June 2026 (Unaudited)

EXHIBIT B (CONTINUED)

	Six months period ended		Three months period ended	
	30 June 2026	30 June 2025	30 June 2026	30 June 2025
	AED '000'	AED '000'	AED '000'	AED '000'
Profit for the period	68,468	69,684	41,789	40,787
Other comprehensive (loss)/income:				
<i>Items that will not be reclassified subsequently to profit or loss:</i>				
(Decrease)/increase in fair value of investments at FVTOCI	(24,899)	24,862	3,450	16,263
Net other comprehensive (loss)/income	(24,899)	24,862	3,450	16,263
Total comprehensive income for the period – Exhibit C	43,569	94,546	45,239	57,050
Attributable to :				
Equity holders of the parent company	30,838	82,316	38,331	51,245
Non-controlling interest	12,731	12,230	6,908	5,805
Net Amount	43,569	94,546	45,239	57,050

THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim statement of changes in equity
For the six months period ended 30 June 2026 (Unaudited)

EXHIBIT C

Attributable to equity holders of the parent company

	Share capital AED '000'	Reserves AED '000'	Cumulative change in fair value of investments at - FVTOCI AED '000'	Retained earnings AED '000'	Total AED '000'	Non-controlling interest AED '000'	Total AED '000'
Balance at 1 January 2025 (Audited)	698,916	306,223	18,447	145,763	1,169,349	91,033	1,260,382
Profit for the Six months period ended 30 June 2025 - Exhibit B	--	--	--	57,454	57,454	12,230	69,684
Other comprehensive income	--	--	24,862	--	24,862	--	24,862
Total comprehensive income (Unaudited)	--	--	24,862	57,454	82,316	12,230	94,546
Cash dividends	--	--	--	(104,837)	(104,837)	--	(104,837)
Board of directors remuneration	--	--	--	(7,000)	(7,000)	--	(7,000)
Balance at 30 June 2025 (Unaudited)	698,916	306,223	43,309	91,380	1,139,828	103,263	1,243,091
Balance at 1 January 2026 (Audited)	698,916	317,074	73,252	131,583	1,220,825	117,692	1,338,517
Profit for the Six months period ended 30 June 2026 - Exhibit B	--	--	--	55,737	55,737	12,731	68,468
Other comprehensive loss	--	--	(24,899)	--	(24,899)	--	(24,899)
Total comprehensive income (Unaudited)	--	--	(24,899)	55,737	30,838	12,731	43,569
Cash dividends – Note 25	--	--	--	(118,816)	(118,816)	--	(118,816)
Board of directors remuneration	--	--	--	(9,000)	(9,000)	--	(9,000)
Balance at 30 June 2026 (Unaudited) - Exhibit A	698,916	317,074	48,353	59,504	1,123,847	130,423	1,254,270

THE ACCOMPANYING NOTES CONSTITUTE AN
INTEGRAL PART OF THESE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

GULF MEDICAL PROJECTS COMPANY (PJSC)
Condensed consolidated interim statement of cash flows
For the six months period ended 30 June 2026 (Unaudited)

EXHIBIT D

	<u>Six months period ended</u>	
	<u>30 June 2026</u>	<u>30 June 2025</u>
	AED '000'	AED '000'
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit for the period before tax – Exhibit B	73,043	74,525
Adjustments for:		
Depreciation of property and equipment	13,803	13,543
Depreciation of right-of-use assets	1,267	1,286
Amortization of intangible assets	231	225
Fair value gain on revaluation of investments at FVTPL	(2,236)	(6,743)
Dividends income	(23,999)	(20,887)
Loss from a related party	307	150
Provision for impairment loss of accounts receivable	10,279	17,393
Gain on sale of property and equipment	(144)	(368)
Provision for slow-moving items	813	--
Employees end of service benefits	3,715	3,386
Finance costs – lease liabilities	48	74
Interest income	(2,914)	(3,330)
Operating cash flows before changes in operating assets and liabilities	74,213	79,254
Increase in inventories	(7,950)	(3,262)
Decrease in due from a related party	70	76
(Increase)/decrease in accounts receivable and others	(33,218)	2,564
Increase in accounts payable and others	10,867	8,763
Settlements of employees end of service benefits	(1,825)	(1,363)
Net Cash Provided by Operating Activities	42,157	86,032
CASH FLOWS FROM INVESTING ACTIVITIES		
Decrease in fixed deposits	56,830	28,991
Interest income received	3,810	3,845
Purchase of property and equipment	(11,554)	(14,219)
Purchase of intangible assets	(5,905)	--
Proceeds from sale of property and equipment	144	370
Purchase of investments at FVTOCI	(9,045)	--
Dividends received	23,999	20,887
Net Cash Provided by Investing Activities	58,279	39,874
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of lease liabilities	(1,251)	(500)
Cash dividends paid	(118,816)	(104,837)
Board of directors remuneration paid	(9,000)	(7,000)
Net Cash Used in Financing Activities	(129,067)	(112,337)
Net (decrease)/increase in cash and cash equivalents	(28,631)	13,569
Cash and cash equivalents at beginning of period	49,304	22,952
Cash and Cash Equivalents at end of Period - Note 24	20,673	36,521

**THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

1. STATUS AND ACTIVITIES

Gulf Medical Projects Company – Sharjah (hereinafter referred to as the “**Company**”) is a public shareholding company incorporated in Sharjah by an Amiri Decree No. 48/79 issued by His Highness The Ruler of Sharjah on 2 August 1979.

The main activities of the Company and its subsidiary (together referred to as the “**Group**”) are general hospital, telehealth services and home health care center, advanced first aid training center, hospitals management and establishment of medicine manufacturing factories.

The Company is domiciled in Sharjah city and its registered address is P.O. Box: 5385, Sharjah, United Arab Emirates.

2. BASIS OF PREPARATION

2.1 Statement of compliance

The condensed consolidated interim financial statements for the six months period ended 30 June 2026 have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting”.

Condensed consolidated interim financial statements does not include all of the information and footnotes required for full annual consolidated financial statements prepared in accordance with International Financial Reporting Standards and should be read in conjunction with the Group’s annual consolidated audited financial statements as at and for the year ended 31 December 2025. In addition, results for the six months period ended 30 June 2026 for the Group are not necessarily indicative of the results that may be expected for the financial year ended 31 December 2026.

2.2 Basis of measurement

These condensed consolidated interim financial statements have been prepared on the historical cost basis except for investment properties, land and investment in financial assets which have been measured on the basis of fair value/valuation.

2.3 Functional and presentation currency

These condensed consolidated interim financial statements are presented in UAE Dirham (AED), which is the Group’s functional currency. Amounts in the condensed consolidated interim financial statements are rounded to the nearest Thousand Arab Emirates Dirham (AED ‘000’).

2.4 Use of estimates, assumptions and judgments

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that effect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

In preparing these condensed consolidated interim financial statements the significant judgments made by management in applying the accounting policies and the key sources of estimation uncertainty were the same as that were applied to consolidated financial statements for the year ended 31 December 2025.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

2. BASIS OF PREPARATION (CONTINUED)

2.5 Geopolitical Developments

During the period, geopolitical developments in the Middle East contributed to increased volatility in global and regional markets. Given the rapidly changing circumstances, it is currently not possible to reliably estimate any potential financial impact on the Group. The Group's management continues to monitor these developments and assess their potential impact on the Group's operation, financial position and results of operation in the future reporting periods.

2.6 Basis of consolidation

These condensed consolidated interim financial statements incorporate the condensed interim financial statements of the parent company and entity controlled by the Company (its subsidiary). Control is achieved when :

- The Group has power over the investee.
- The Group is exposed, or has rights, to variable returns from its involvement with the investee.
- The Group has the ability to use its power over the investee to affect its returns.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control mentioned above.

When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts circumstances whether it has power over an investee, including:

- The contractual arrangement with the other vote holders of the investee.
- Rights arising from other contractual arrangements.
- The Group's voting rights and potential voting rights

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed during the period is included in the condensed consolidated interim statement of income from the date the Group gains control until the date when the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributable to the equity holders of the parent company and to the non-controlling interest even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of the subsidiary to bring their accounting policies into line with the Group accounting policies.

All intragroup balances and income, equity and cash flows relating to transactions between entities of the Group are eliminated in full on consolidation.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

2. BASIS OF PREPARATION (CONTINUED)

2.6 Basis of consolidation (Continued)

Changes in the Group ownership interests in the subsidiary that do not result in the Group losing control over the subsidiary is accounted for as equity transactions. The carrying amounts of the Group interests and the non-controlling interest are adjusted to reflect the changes in their relative interests in the subsidiary. Any difference between the amount by which the non-controlling interest are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to owners of the Group.

The details of the subsidiary is as follows :

<u>Company</u>	<u>% of ownership</u>		<u>Principal activities</u>	<u>Country of incorporation</u>
	<u>30 June 2026</u>	<u>31 December 2025</u>		
Al Zahra (Pvt.) Hospital Dubai (L.L.C)	68.38	68.38	General Hospital, home healthcare center and telehealth services and advance first aid training center.	UAE

3. MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies used in the preparation of these condensed consolidated interim financial statements are consistent with those used in the Group's audited annual consolidated financial statements for the year ended 31 December 2025.

The new revised relevant IFRSs effective from 1 January 2026 had no material impact on the condensed consolidated interim financial position or performance of the Group during the period.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements
For the six months period ended 30 June 2026

4. PROPERTY AND EQUIPMENT

a) The details of this item are as follows :

	Land AED '000'	Hospital buildings AED '000'	Hospital furniture and equipment AED '000'	Motor vehicles AED '000'	Other furniture and equipment AED '000'	Capital work- in-progress AED '000'	Total AED '000'
Cost/Revaluation :							
At 1 January 2025	250,482	582,362	162,500	4,963	17,529	2,865	1,020,701
Additions during the year	--	3,152	17,413	1,292	407	4,497	26,761
Disposals during the year	--	--	(775)	(823)	(243)	--	(1,841)
At 31 December 2025	250,482	585,514	179,138	5,432	17,693	7,362	1,045,621
Additions during the period	--	814	10,406	--	258	76	11,554
Disposals during the period	--	--	--	(303)	--	--	(303)
Balance at 30 June 2026	250,482	586,328	189,544	5,129	17,951	7,438	1,056,872
Accumulated Depreciation :							
At 1 January 2025	--	175,940	129,148	3,558	16,333	--	324,979
Charged for the year	--	16,319	10,026	532	493	--	27,370
Relating to disposals	--	--	(747)	(823)	(243)	--	(1,813)
At 31 December 2025	--	192,259	138,427	3,267	16,583	--	350,536
Charged for the period	--	8,123	5,176	315	189	--	13,803
Relating to disposals	--	--	--	(303)	--	--	(303)
Balance at 30 June 2026	--	200,382	143,603	3,279	16,772	--	364,036
Net Book Value							
At 30 June 2026 - Exhibit A (Unaudited)	250,482	385,946	45,941	1,850	1,179	7,438	692,836
At 31 December 2025 - Exhibit A (Audited)	250,482	393,255	40,711	2,165	1,110	7,362	695,085

b) Land of AED. 250,482 thousand mentioned above represents the fair value of a plot of land at date of acquisition measuring 350,000 square feet registered with the concerned government department in the name of the subsidiary.

c) Capital work-in-progress of AED. 7,438 thousand mentioned above represent the costs incurred for the heat pumps and accessories and redesign and renovation works at the hospital buildings in the Emirate of Dubai.

d) Depreciation for the period is allocated to cost of revenues and general and administrative expenses amounting to AED. 13,555 thousand (At 30 June 2025 : AED. 13,326 thousand) and AED. 248 thousand (At 30 June 2025 : AED. 217 thousand), respectively.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements
For the six months period ended 30 June 2026

5. INTANGIBLE ASSETS

a) This item consists of the following :

	<u>Software</u> <u>AED '000'</u>
Cost	
At 1 January 2025	3,935
Additions	2,344
At 31 December 2025	6,279
Additions	5,905
Balance at 30 June 2026	12,184
Accumulated Amortization	
At 1 January 2025	3,200
Charged for the year	579
At 31 December 2025	3,779
Charged for the period	231
Balance at 30 June 2026	4,010
Net book Value	
At 30 June 2026 – Exhibit A (Unaudited)	8,174
At 31 December 2025 – Exhibit A (Audited)	2,500

b) Amortization for the period is allocated to cost of revenues and general administrative expenses amounting to AED. 230 thousand (At 30 June 2025 : AED. 224 thousand) and AED. 1 thousand (At 30 June 2025 : AED. 1 thousand) respectively.

6. RIGHT-OF-USE ASSETS

The movement of right-of-use assets are summarized as follows :

	<u>30 June 2026</u> <u>(Unaudited)</u> <u>AED '000'</u>	<u>31 December 2025</u> <u>(Audited)</u> <u>AED '000'</u>
At 1 January	6,729	7,353
Addition during the period/year	--	1,963
Charged for the period/year	(1,267)	(2,587)
Net balance at the end of the period/year – Exhibit A	5,462	6,729

7. INVESTMENT PROPERTIES

a) This item consists of the following :

	<u>30 June 2026</u> <u>(Unaudited)</u> <u>AED '000'</u>	<u>31 December 2025</u> <u>(Audited)</u> <u>AED '000'</u>
Fair value at 1 January	106,295	104,181
Increase in fair value	--	2,114
Fair Value at end of the period/year – Exhibit A	106,295	106,295

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

7. INVESTMENT PROPERTIES (CONTINUED)

b) Investment properties of AED. 106,295 thousand mentioned above represent the fair value as at 30 June 2026, based on management estimate.

c) Investment properties represent investments in land and real estates in the United Arab Emirates.

8. INVESTMENTS IN FINANCIAL ASSETS

Investments in financial assets comprise of the following :

a) Investments at fair value through other comprehensive income (FVTOCI)

This item consists of the following :

	30 June 2026 (Unaudited) AED '000'	31 December 2025 (Audited) AED '000'
Fair value at 1 January	305,649	250,307
Purchases during the period/year	9,045	537
(Decrease)/increase in fair value	(24,899)	54,805
Fair value at end of the period/year – Exhibit A	289,795	305,649

Investments at fair value through other comprehensive income represent investments in securities quoted in the local financial markets.

b) Investments at fair value through profit or loss (FVTPL)

This item consists of the following :

	30 June 2026 (Unaudited) AED '000'	31 December 2025 (Audited) AED '000'
Fair value at 1 January	60,661	36,567
Increase in fair value	2,236	24,094
Fair Value at end of the period/year - Exhibit A	62,897	60,661

Investments at fair value through profit or loss represent investment in securities quoted in local and regional financial markets.

9. INVENTORIES

a) This item consists of the following :

	30 June 2026 (Unaudited) AED '000'	31 December 2025 (Audited) AED '000'
Goods for sale (drugs and cosmetics)	22,717	18,228
General stores and hospital supplies	13,329	9,868
Provision for slow-moving items – Note 9(b)	(1,882)	(1,069)
Net Amount – Exhibit A	34,164	27,027

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements
For the six months period ended 30 June 2026

9. INVENTORIES (CONTINUED)

b) The details of movement in provision for slow-moving items are as follows:

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Balance at 1 January	1,069	590
Addition during the period/year	813	1,118
Written off during the period/year	--	(639)
Balance at the end of the period/year – Note 9(a)	<u>1,882</u>	<u>1,069</u>

10. BALANCES AND TRANSACTIONS WITH RELATED PARTIES

In the normal course of business, the Group enters into various transactions with related parties. Related parties represent major shareholders, directors and key management personnel of the group, and entities controlled, jointly controlled or significantly influenced by such parties. The prices and terms of these transactions are agreed with the Group's management.

- Due from a related party**

This item represents the amount due from Gulf Medical Commercial Agencies (LLC) – Sharjah. As per the management contract the Company is managed and financed by the Group in return for obtaining all the profit/(losses) generated by the Company which has been included in the condensed consolidated interim statement of income for the Group. The details of the movement in this account are as follows :

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Balance at 1 January	1,646	1,832
Net funds (paid)/received	(70)	28
Loss for the period/year transferred	(307)	(214)
Balance at end of the period/year – Exhibit A	<u>1,269</u>	<u>1,646</u>

- The following are the details of significant related parties transactions :

	<u>Six months period ended</u> <u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>30 June 2025</u> <u>(Unaudited)</u> AED '000'
Purchases	305	317
Expenses	265	265

- The remuneration, salaries and other benefits of Board of Directors and other members of key management during the period are as follows :

	<u>Six months period ended</u> <u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>30 June 2025</u> <u>(Unaudited)</u> AED '000'
Board of directors remuneration (as approved by the Annual General Meeting)	9,000	7,000
Key management salaries and other related benefits	5,862	5,034
Board committee expenses	100	105

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

11. ACCOUNTS RECEIVABLE AND OTHERS

a) This item consists of the following :

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Accounts receivable	237,388	222,043
Provision for impairment loss of accounts receivable – Note 11(b)	(129,138)	(119,059)
Net Amount	108,250	102,984
Prepaid expenses	8,933	4,815
Recoverable tax (VAT)	3,149	2,306
Post-dated cheques received	272	1,180
Refundable deposits	1,215	1,215
Interest receivable	798	1,694
Staff receivables	42	44
Margin held with banks	982	959
Advances paid	16,780	3,165
Due from brokerage companies	82	83
Others	--	15
Total - Exhibit A	<u>140,503</u>	<u>118,460</u>

b) The details of movement in provision for impairment loss of accounts receivable are as follows:

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Balance at 1 January	119,059	117,929
Addition during the period/year	10,279	34,638
Written off during the period/year	(200)	(33,508)
Balance at the end of the period/year – Note 11(a)	<u>129,138</u>	<u>119,059</u>

12. CASH AND BANK BALANCES

This item consists of the following :

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Cash in hand	273	304
Bank balances - Current and call deposit accounts	20,400	49,000
Fixed deposits	117,287	174,117
Total - Exhibit A	<u>137,960</u>	<u>223,421</u>

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

13. SHARE CAPITAL

This item consists of the following :

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Authorized share capital is 698,916,094 ordinary shares of AED. 1 each fully paid – Exhibit A	698,916	698,916

14. NON-CONTROLLING INTEREST

a) The details of movement in this item during the period/year are as follows :

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Balance at 1 January	117,692	91,033
Share of profit for the period/year	12,731	26,659
Balance at end of the period/year - Exhibit A	130,423	117,692

b) Non-controlling interest mentioned above represents the share of non-controlling as at the condensed consolidated interim statement of financial position date and are as follows:

	<u>30 June 2026</u> <u>(Unaudited)</u> %	<u>31 December 2025</u> <u>(Audited)</u> %
Share in Al Zahra (Pvt) Hospital Dubai (L.L.C)	31.62	31.62

15. EMPLOYEES' END OF SERVICE BENEFITS

The details of movement in this item during the period/year are as follows:

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Balance at 1 January	31,481	28,102
Current service cost	3,715	6,892
Settlements	(1,825)	(3,513)
Balance at end of the period/year – Exhibit A	33,371	31,481

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

16. LEASE LIABILITIES

Lease liabilities represent the long term leases of staff accommodation and robotics surgical systems up to the year 2029. The details of movement in this item during the period/year are as follows :

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Balance at 1 January	6,268	5,920
Additions during the period/year	--	1,963
Interest on lease liabilities for the period/year	48	136
Payments during the period/year	(1,251)	(1,751)
Balance at the end of the period/year	5,065	6,268
Non-Current – Exhibit A	2,337	3,100
Current – Exhibit A	2,728	3,168
Total	5,065	6,268

17. ACCOUNTS PAYABLE AND OTHERS

This item consists of the following :

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Accounts payable	90,861	84,575
Uncollected portion of repayments to shareholders	1,070	1,070
Post -dated cheques issued	17,724	9,562
Accrued expenses	20,236	12,383
Provision for staff leave salaries and air passage	21,346	17,423
Income received in advance	2,104	2,142
Staff payables	12	93
Others	16,404	31,642
Total - Exhibit A	169,757	158,890

18. SEGMENT INFORMATION

The Board of Directors are chief operating decision makers. Management determine the operation segments based on segments identified for the purpose of allocation resources and assessing performance.

The Group's reportable segments are organized into two major segments as follows:

- | | |
|-------------------------------|--|
| i) Health services and others | Principally providing health, medical care and other related services. |
| ii) Investments | Principally concerned with investment properties and investment in securities. |

Performance of each segment is measured based on segment profit as management believes that profit is the most relevant factor in evaluating the results of segment.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements
For the six months period ended 30 June 2026

18. SEGMENT INFORMATION (CONTINUED)

The financial analysis according to the business segments are as follows :

	<u>Health Services & others</u>		<u>Investments</u>		<u>Total</u>	
	<u>Six months period ended</u>	<u>30 June 2025</u>	<u>Six months period ended</u>	<u>30 June 2025</u>	<u>Six months period ended</u>	<u>30 June 2025</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>
Revenues						
Total revenues	405,239	365,419	30,338	32,005	435,577	397,424
Result						
Segment result	102,591	96,399	30,206	31,895	132,797	128,294
Unallocated general and administrative expenses					(66,461)	(65,915)
Operating profit					66,336	62,379
Other income	6,707	12,146	--	--	6,707	12,146
Profit from operation before tax					73,043	74,525
Current income tax expenses					(4,290)	(4,234)
Deferred tax					(285)	(607)
Profit from operation					68,468	69,684
Attributable to non-controlling interest					(12,731)	(12,230)
Profit for the period					55,737	57,454

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

18. SEGMENT INFORMATION (CONTINUED)

	Health Services & others		Investments		Total	
	30 June 2026 (Unaudited) AED '000'	31 December 2025 (Audited) AED '000'	30 June 2026 (Unaudited) AED '000'	31 December 2025 (Audited) AED '000'	30 June 2026 (Unaudited) AED '000'	31 December 2025 (Audited) AED '000'
Other information						
Segment assets	892,315	891,456	587,040	656,017	1,479,355	1,547,473
Segment liabilities	215,065	199,298	10,020	9,658	225,085	208,956
Capital expenditure	17,459	29,105	--	--	17,459	29,105

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

19. REVENUES

a) This item consists of the following :

	<u>Six months period ended</u>		<u>Three months period ended</u>	
	<u>30 June 2026</u>	<u>30 June 2025</u>	<u>30 June 2026</u>	<u>30 June 2025</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	AED '000'	AED '000'	AED '000'	AED '000'
Revenue from contracts with customers - Exhibit B	405,239	365,419	210,850	185,366

b) Disaggregation of revenue from contracts with customers

Set out below is the disaggregation of the Group's revenue from contracts with customers :

	<u>Six months period ended</u>		<u>Three months period ended</u>	
	<u>30 June 2026</u>	<u>30 June 2025</u>	<u>30 June 2026</u>	<u>30 June 2025</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	AED '000'	AED '000'	AED '000'	AED '000'
<u>Segments</u>				
Type of services				
Revenue from healthcare services	405,239	365,419	210,850	185,366
Geographical markets				
Revenue within UAE	405,239	365,419	210,850	185,366
Timing of revenue recognition				
Services and goods transferred at a point in time	405,239	365,419	210,850	185,366

c) Performance obligations

Information about the Group's performance obligations are summarized below :

Rendering of services

Health care services revenues primarily comprise fees charged for inpatient and outpatient medical services. Services include charges for accommodation, theatre, medical professional services, equipment, laboratory and pharmaceutical items used and recorded at the time of billing.

Sale of goods

Revenue from sale of goods represent the total revenue from sale of drug and cosmetics provided to customers and is recognized when control and benefits are transferred and billed.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

20. COST OF REVENUES

This item consists of the following :

	Six months period ended		Three months period ended	
	30 June 2026	30 June 2025	30 June 2026	30 June 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	AED '000'	AED '000'	AED '000'	AED '000'
Salaries and other related benefits	179,065	158,757	89,696	79,774
Supplies and services	108,531	95,427	60,045	49,908
Depreciation of property and equipment	13,555	13,326	6,742	6,649
Depreciation of right-of-use assets	1,267	1,286	616	643
Amortization of intangible assets	230	224	163	99
Total - Exhibit B	302,648	269,020	157,262	137,073

21. GENERAL AND ADMINISTRATIVE EXPENSES

This item consists of the following :

	Six months period ended		Three months period ended	
	30 June 2026	30 June 2025	30 June 2026	30 June 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	AED '000'	AED '000'	AED '000'	AED '000'
Staff salaries and other related benefits	36,926	32,513	18,564	16,995
Board committee expenses	100	105	42	58
Electricity and water	3,562	3,486	1,966	1,956
Advertising and publicity	2,263	2,388	1,041	1,324
Provision for impairment loss of accounts receivable	10,279	17,393	5,409	8,709
Provision for slow-moving items	813	--	--	--
Government expenses	3,372	3,468	1,484	1,585
Telephone and postage	542	381	276	194
Insurance	756	953	248	574
Legal and professional fees	1,411	1,924	605	1,108
Banks and credit card charges	1,058	1,084	513	529
Depreciation of property and equipment	248	217	123	120
Amortization of intangible assets	1	1	--	--
IT expenses	3,040	--	1,921	--
Miscellaneous expenses	2,042	1,928	902	798
Total - Exhibit B	66,413	65,841	33,094	33,950

22. INCOME TAX*Corporate Tax Law*

On 9 December 2022, the UAE Ministry of Finance released Federal Decree-Law No. 47 of 2022 on the Taxation of Corporations and Businesses, Corporate Tax Law ("CT Law") to enact a Federal corporate tax regime in the UAE. Furthermore, a Cabinet Decision was published which specifies that taxable income not exceeding AED. 375,000 would be subject to a 0% UAE CT rate and taxable income exceeding AED. 375,000 would be subject to the 9% UAE CT rate.

The effective implementation date for the Group starts from 1 January 2024.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2026

22. INCOME TAX (CONTINUED)

Corporate Tax Law (Continued)

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed consolidated interim statement of income are as follows :

Current income tax:

The movement in this item during the period/year are as follows:

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Balance at 1 January	9,035	8,181
Current tax expenses for the period/year	4,290	9,033
Paid during the period/year	--	(8,179)
Balance at end of the period/year – Exhibit A	13,325	9,035

The income tax expenses for current period ended 30 June 2026 is AED. 4,290 thousand (30 June 2025: AED. 4,234 thousand) - **Exhibit B** and the effective current income tax rate for the period 5.87% (30 June 2025: 5.68%)

Deferred tax:

The movement in this item during the period/year are as follows:

	<u>30 June 2026</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2025</u> <u>(Audited)</u> AED '000'
Balance at 1 January	3,282	923
Deferred tax liabilities for the period/year	285	2,359
Balance at end of the period/year – Exhibit A	3,567	3,282

The deferred tax liabilities of AED. 285 thousand (30 June 2025: AED. 607 thousand) - **Exhibit B**, as determined by the Group's management assessment, arising from temporary differences related to the fair value changes in assets measured at fair value and provision for impairment loss of accounts receivable as of the condensed consolidated interim statement of financial position date.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements
For the six months period ended 30 June 2026

23. BASIC EARNINGS PER SHARE

This item consists of the following :

	<u>Six months period ended</u>		<u>Three months period ended</u>	
	<u>30 June 2026</u>	<u>30 June 2025</u>	<u>30 June 2026</u>	<u>30 June 2025</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
Profit for the period attributable to equity holders of the Parent Company (AED '000')	<u>55,737</u>	<u>57,454</u>	<u>34,881</u>	<u>34,982</u>
Weighted average number of shares (Share '000')	<u>698,916</u>	<u>698,916</u>	<u>698,916</u>	<u>698,916</u>
Basic earnings per share (AED) - Exhibit B	<u>0.080</u>	<u>0.082</u>	<u>0.050</u>	<u>0.050</u>

24. CASH AND CASH EQUIVALENTS

At 30 June 2026 and 2025 "cash and cash equivalents" included in the condensed consolidated interim statement of cash flows (Exhibit D) comprise the following items :

	<u>Six months period ended</u>	
	<u>30 June 2026</u>	<u>30 June 2025</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	<u>AED '000'</u>	<u>AED '000'</u>
Cash in hand	<u>273</u>	<u>237</u>
Bank balances – Current and call accounts	<u>20,400</u>	<u>36,284</u>
Total - Exhibit D	<u>20,673</u>	<u>36,521</u>

25. DIVIDEND AND DIRECTORS' REMUNERATION

- At the Annual General Meeting held on 26 March 2026, the shareholders approved 17% cash dividend proposed by the Board of Directors.
- At the Annual General Meeting held on 26 March 2026, the shareholders approved the proposed Board of Directors' remuneration amounting to AED. 9,000 thousand for the year ended 31 December 2025.

26. CONTINGENT LIABILITIES/COMMITMENTS**i) Contingent liabilities**

Contingent liabilities of the Group as at the condensed consolidated interim statement of financial position date amounted to AED. 982 thousand (Unaudited) [(31 December 2025: AED. 959 thousand) (Audited)] representing guarantees issued.

ii) Commitments

Commitments of the group as at the condensed consolidated interim statement of financial position date are as follows :

	<u>30 June 2026</u>	<u>31 December 2025</u>
	<u>(Unaudited)</u>	<u>(Audited)</u>
	<u>AED '000'</u>	<u>AED '000'</u>
Capital purchases	<u>41,948</u>	<u>37,824</u>